As AKT and mTOR kinases are crucial regulators of prostate cancer cell growth, proliferation and survival, treatment of high grade tumours with an AKT kinase inhibitor (AZD7328) and mTOR kinase inhibitor (KU-0063794), both ATP-competitive small molecules, has been proposed as a promising treatment strategy in oncology [6–8]. Here, AKT1 is linked to neoplasm.